Molecular Templates Inc (MTEM) has provided an announcement.
Molecular Templates, Inc. teamed up with Bristol Myers Squibb (BMS) in a promising collaboration to develop new products using its engineered toxin body (ETB) technology. However, the partnership hit a snag when BMS decided to end the agreement, which will cease in June 2024. This change prompts Molecular Templates to cut costs tied to the deal and shift focus to advancing its own clinical-stage programs.
Find detailed analytics on MTEM stock on TipRanks’ Stock Analysis page.
